Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Source: onclive.com
Zuma 23 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Zuma 23. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Zuma 23 Today - Breaking & Trending Today
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma
Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Source: onclive.com